CDKN2A and non-small cell lung carcinoma: We now report results of a phase 2 clinical trial studying the efficacy of palbociclib alone in patients with previously-treated advanced NSCLC who were preselected for CDKN2a/p16 loss using immunohistochemistry and who had radiographic evidence for documented tumor progression at enrollment.